About
About Jinling Pharmaceutical Company Limited
Jinling Pharmaceutical Company Limited, together with its subsidiaries, manufactures and sells pharmaceuticals and medical devices in China and internationally. It offers Mailuoning injection and oral solution for the treatment of thromboangiitis and arteriosclerosis obliterans, as well as cerebral and venous thrombosis; Sulifei, a ferrous succinate tablet for the prevention and treatment of iron deficiency anemia; Lentinan injection, an adjuvant therapy for the treatment of malignant tumors; and absorbable gelatin sponges for the treatment of wound bleeding and trauma hemostasis. The company also provides traditional Chinese medicines, chemical medicines, active pharmaceutical ingredients, and pharmaceutical intermediates. In addition, it engages in elderly care services, rehabilitation therapy, psychological counseling, and end-of-life care; hospital management; technical services; and healthcare investment activities. The company was incorporated in 1998 and is headquartered in Nanjing, China.
Visit company website
5 years, 6 months ago
Jinling Pharmaceutical Company Limited is currently in a long term uptrend where the price is trading 0.7% above its 200 day moving average.
From a valuation standpoint, the stock is 86.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.3.
Jinling Pharmaceutical Company Limited's total revenue rose by 15.2% to $685M since the same quarter in the previous year.
Its net income has increased by 86.3% to $-12M since the same quarter in the previous year.
Finally, its free cash flow fell by 96.3% to $4M since the same quarter in the previous year.
Based on the above factors, Jinling Pharmaceutical Company Limited gets an overall score of 4/5.